Volume 135, Issue 1, Pages (July 2008)

Slides:

Advertisements

Similar presentations

Volume 143, Issue 3, Pages e1 (September 2012)

Advertisements

Volume 135, Issue 5, Pages (November 2008)

Volume 134, Issue 7, Pages (June 2008)

Volume 148, Issue 4, Pages (April 2015)

Oral Viscous Budesonide Is Effective in Children With Eosinophilic Esophagitis in a Randomized, Placebo-Controlled Trial Ranjan Dohil, Robert Newbury,

Volume 136, Issue 5, Pages (May 2009)

Volume 153, Issue 3, Pages e7 (September 2017)

Volume 153, Issue 3, Pages e7 (September 2017)

Outcomes Among Living Liver Donors

Unusual Cause of Elevated Liver Enzymes in a Female Patient

Volume 135, Issue 4, Pages (October 2008)

Ira J. Fox, Stephen C. Strom Gastroenterology

Volume 149, Issue 2, Pages (August 2015)

Volume 141, Issue 2, Pages (August 2011)

Amnon Sonnenberg, Richard H. Lash, Robert M. Genta Gastroenterology

Volume 141, Issue 4, Pages e2 (October 2011)

Gastroenterology 2011–2016: Looking Back and Forward

Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement Glen Lutchman,

Liver fibrosis in overweight patients

Volume 128, Issue 7, Pages (June 2005)

Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial David Houghton, Christian.

Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus–Related Cirrhosis: A Randomized Trial Laetitia Fartoux, Françoise Degos, Christian.

Unusual Case of an Upset Stomach

Volume 134, Issue 7, Pages (June 2008)

Volume 150, Issue 4, Pages (April 2016)

Volume 155, Issue 1, Pages (July 2018)

Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States Constance E. Ruhl, James E.

Volume 137, Issue 2, Pages (August 2009)

A Double-Blind Randomized Placebo-Controlled Trial of Orlistat for the Treatment of Nonalcoholic Fatty Liver Disease Shira Zelber–Sagi, Ada Kessler,

Abstracts from Around the World

This Month in Gastroenterology

Volume 149, Issue 2, Pages (August 2015)

Volume 145, Issue 1, Pages (July 2013)

Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis Jean–François Dufour, Carl M. Oneta, Jean–Jacques.

Rohit Loomba, MD, MHSc Clinical Gastroenterology and Hepatology

This Month in Gastroenterology

Volume 136, Issue 5, Pages (May 2009)

Michel I. Kafrouni, Robert A. Anders, Sumita Verma

Volume 141, Issue 4, Pages e3 (October 2011)

Volume 155, Issue 6, Pages (December 2018)

Volume 150, Issue 5, Pages e5 (May 2016)

Chan Wah Kheong, Nik Raihan Nik Mustapha, Sanjiv Mahadeva

Covering the Cover Gastroenterology

Postprandial Uridine Physiology Is Altered by Obesity

Volume 149, Issue 2, Pages e5 (August 2015)

Volume 150, Issue 3, Pages (March 2016)

Covering the Cover Gastroenterology

Volume 135, Issue 5, Pages (November 2008)

Reduced Mortality Rates Following Elective Percutaneous Liver Biopsies

Volume 136, Issue 7, Pages (June 2009)

A Selection of the Best AGA Abstracts of DDW 2017

Volume 133, Issue 2, Pages (August 2007)

Ashwin N. Ananthakrishnan, David Lieberman Gastroenterology

Covering the Cover Gastroenterology

Jeremy P. Dwyer, Patrick Hosking, John Lubel Gastroenterology

Refining Sample-Size Estimations Based Upon Placebo Response in Trials of Agents for Nonalcoholic Fatty Liver Disease Veeral Ajmera, MD, MAS, Rohit Loomba,

Volume 136, Issue 7, Pages (June 2009)

Association Between Reduced Levels of Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing Cholangitis Lina Lindström, Rolf Hultcrantz,

The Dawning of a New Editorial Board for Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

Volume 143, Issue 3, Pages e1 (September 2012)

Changing of the Guards: 2011–2016 Gastroenterology Team

Volume 155, Issue 6, Pages (December 2018)

Volume 139, Issue 6, Pages e1 (December 2010)

Trunk Fat as a Determinant of Liver Disease

Volume 134, Issue 3, Pages (March 2008)

Controversies in Liver Transplantation for Hepatitis C

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Covering the Cover Gastroenterology

Volume 135, Issue 5, Pages (November 2008)

Presentation transcript:

Volume 135, Issue 1, Pages 100-110 (July 2008) Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial Vlad Ratziu, Philippe Giral, Sophie Jacqueminet, Fréderic Charlotte, Agnès Hartemann–Heurtier, Lawrence Serfaty, Philippe Podevin, Jean–Marc Lacorte, Carole Bernhardt, Eric Bruckert, André Grimaldi, Thierry Poynard Gastroenterology Volume 135, Issue 1, Pages 100-110 (July 2008) DOI: 10.1053/j.gastro.2008.03.078 Copyright © 2008 AGA Institute Terms and Conditions

Figure 1 Difference in the histologic score for steatosis between EOT and baseline liver biopsy specimens in both rosiglitazone (black circles) and placebo (white circles). Steatosis is expressed as the percentage of hepatocytes containing fat droplets. Responders for steatosis (ie, patients having lost >30% during treatment) are those on or below the dashed line. Gastroenterology 2008 135, 100-110DOI: (10.1053/j.gastro.2008.03.078) Copyright © 2008 AGA Institute Terms and Conditions

Figure 2 ALT course during therapy. Results are expressed as means (±SD) of fold elevation over baseline values at each time point during treatment and at EOT (month 12) and end of follow-up (month 16). (A) Rosiglitazone (black circles) and placebo (white circles); mean ALT values were significantly lower in the rosiglitazone group at months 4, 8, and 12. (B) Responders for steatosis (black circles) and nonresponders (white circles); mean ALT values were significantly lower in responders at months 8 and 12. Gastroenterology 2008 135, 100-110DOI: (10.1053/j.gastro.2008.03.078) Copyright © 2008 AGA Institute Terms and Conditions

Figure 3 Changes in serum adiponectin levels during treatment. (A) Serum adiponectin level at baseline (month 0 [M0]) and at EOT in patients treated with rosiglitazone (n = 12) and those receiving placebo (n = 10); P = .04; error bars represent SD. (B) Correlation between changes in serum adiponectin level (ratio EOT/M0) and changes in histologic score of steatosis during treatment (difference between steatosis on the EOT biopsy and baseline biopsy, EOT-M0); r = −0.54, P < .01, Spearman ranked test). Gastroenterology 2008 135, 100-110DOI: (10.1053/j.gastro.2008.03.078) Copyright © 2008 AGA Institute Terms and Conditions